Novo Nordisk A/S
FACTOR X BINDERS ENHANCING FX ACTIVATION
Last updated:
Abstract:
The application relates to unique FX binding molecules, such as antibodies and fragments thereof which are useful in the treatment of haemophilia.
Status:
Application
Type:
Utility
Filling date:
15 Nov 2018
Issue date:
25 Feb 2021